Publication:
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Simple item page
dc.contributor.authorSeferović, Petar M. (6603594879)
dc.contributor.authorFragasso, Gabriele (7005496913)
dc.contributor.authorPetrie, Mark (7006426382)
dc.contributor.authorMullens, Wilfried (55916359500)
dc.contributor.authorFerrari, Roberto (36047514600)
dc.contributor.authorThum, Thomas (57195743477)
dc.contributor.authorBauersachs, Johann (7004626054)
dc.contributor.authorAnker, Stefan D. (56223993400)
dc.contributor.authorRay, Robin (57194275026)
dc.contributor.authorÇavuşoğlu, Yuksel (7003632889)
dc.contributor.authorPolovina, Marija (35273422300)
dc.contributor.authorMetra, Marco (7006770735)
dc.contributor.authorAmbrosio, Giuseppe (35411918900)
dc.contributor.authorPrasad, Krishna (57209824663)
dc.contributor.authorSeferović, Jelena (23486982900)
dc.contributor.authorJhund, Pardeep S. (6506826363)
dc.contributor.authorDattilo, Giuseppe (24073159500)
dc.contributor.authorČelutkiene, Jelena (6507133552)
dc.contributor.authorPiepoli, Massimo (7005292730)
dc.contributor.authorMoura, Brenda (6602544591)
dc.date.accessioned2025-06-12T13:58:13Z
dc.date.available2025-06-12T13:58:13Z
dc.date.issued2020
dc.description.abstractThe Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus. © 2020 European Society of Cardiology
dc.identifier.urihttps://doi.org/10.1002/ejhf.2026
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85094593637&doi=10.1002%2fejhf.2026&partnerID=40&md5=b45b15200476429baf2b84f0cef0fb4a
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/4649
dc.subjectCardiovascular outcomes
dc.subjectHeart failure
dc.subjectRenal function
dc.subjectSodium–glucose co-transporter 2 inhibitors
dc.subjectType 2 diabetes mellitus
dc.titleHeart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure
dspace.entity.typePublication

Files

Collections

Publikacije / Publications